Frontlight ResearchEarly access
CompletedPhase 2
This is a clinical trial (study), to be conducted at multiple clinical sites, of an oral study drug (EP262) that will be investigated in adult participants with Chronic Spontaneous Urticaria (CSU) to assess if it is effective and safe.
Key facts
- Who runs it
- Escient Pharmaceuticals Inc.
- Where
- Germany, Netherlands, Poland, and Spain16 sites in 4 countriesChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 44 people enrolled
- Started
- 20 Feb 2024
- Ended
- 3 Mar 2025
- Type of study
- Interventional
- Record updated
- 24 February 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Age 18 to 80 years
- Documented history of chronic spontaneous urticaria (CSU) with a UAS7 greater than or equal to 16 despite stable treatment with H1 antihistamine consistent with standard of care
- Must be on a stable dose of H1 antihistamine up to 4 times the approved dose per local treatment guidelines
Who cannot take part
- Other active skin diseases associated with chronic pruritus (eg, atopic dermatitis, bullous pemphigoid, prurigo nodularis, dermatitis herpetiformis)
- Urticaria with a clear underlying etiology other than CSU
- Urticaria with a clearly defined or sole trigger (chronic inducible urticaria)
This trial has no sites in United States.
It has sites in 4 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
To evaluate the efficacy of EP262 compared to placebo in participants with CSU.
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects with Chronic Spontaneous Urticaria
- Record updated
- 24 February 2025